NeuroVive Pharmaceutical AB organizacji Cena/Sprzedaż
Jaka jest wartość Cena/Sprzedaż organizacji NeuroVive Pharmaceutical AB?
Wartość Cena/Sprzedaż organizacji NeuroVive Pharmaceutical AB to 1,207.19
Jaka jest definicja Cena/Sprzedaż?
Wskaźnik ceny do zysku (Price to sales ratio) to wskaźnik reprezentuje koszt firmy w porównaniu do kwoty jej sprzedaży.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Cena/Sprzedaż firm w Miscellaneous sektor na LSE w porównaniu do NeuroVive Pharmaceutical AB
Czym się zajmuję organizacja NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Firmy z cena/sprzedaż podobne do NeuroVive Pharmaceutical AB
- Wartość Cena/Sprzedaż organizacji CytoDyn to 1,174.39
- Wartość Cena/Sprzedaż organizacji Cellular Biomedicine Inc to 1,184.26
- Wartość Cena/Sprzedaż organizacji Black Rock Mining to 1,188.66
- Wartość Cena/Sprzedaż organizacji Navidea Biopharmaceuticals Inc to 1,194.84
- Wartość Cena/Sprzedaż organizacji Kraig Biocraft Laboratories to 1,199.03
- Wartość Cena/Sprzedaż organizacji Buderim to 1,206.67
- Wartość Cena/Sprzedaż organizacji NeuroVive Pharmaceutical AB to 1,207.19
- Wartość Cena/Sprzedaż organizacji Strategic Elements Ltd to 1,216.32
- Wartość Cena/Sprzedaż organizacji Greenland Minerals to 1,251.46
- Wartość Cena/Sprzedaż organizacji Galantas Gold to 1,271.42
- Wartość Cena/Sprzedaż organizacji Kazia Therapeutics to 1,276.66
- Wartość Cena/Sprzedaż organizacji Tyranna Resources to 1,282.36
- Wartość Cena/Sprzedaż organizacji Leading Leasing Finance And Investment to 1,283.53